Cure8
Influence of initial axial involvement on the phenotypic evolution of axial spondyloarthritis: 10-year data from the DESIR cohort.
RMD open

Cure8 research brief

Influence of initial axial involvement on the phenotypic evolution of axial spondyloarthritis: 10-year data from the DESIR cohort.

1 min read
Complications Clinical study

Why This Matters

If your inflammatory back pain involves both upper and lower spine early on, this study suggests you may have a higher chance of developing peripheral arthritis later — information that could affect monitoring and discussions about long-term risk.

Who Should Pay Attention

Clinicians treating early axSpA, rheumatology researchers studying disease progression, and patients with early axial spondyloarthritis who have multi-level (diffuse) axial pain.

Study Snapshot

Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract

What To Know

The study followed 662 patients with early axSpA and categorized initial pain location as cervicothoracic, lumbosacral, or diffuse. After adjusting for age, sex and use of conventional and biologic DMARDs, diffuse initial involvement was associated with a higher risk of later peripheral arthritis (hazard ratio reported in the paper).

This finding suggests that the anatomical pattern of early axial pain may help identify a subgroup at higher risk for developing peripheral joint inflammation, which could inform early risk discussions and influence monitoring or trial interpretation.

Keep In Mind

The content is based on the PubMed abstract (DESIR cohort, 10-year follow-up). Association does not prove causation; the study adjusted for some treatments and baseline features but further research could clarify mechanisms and clinical implications.

Source Details

Review the original publication for the complete reporting, methods, and context.

Read Original Source
Research paper Evidence type derived from source or registry metadata.
PublicationRMD open
AuthorsAudrey-Anne Couture, Bastien Peiffer, Philippe Le Corvoisier +5 more
InstitutionService de Rhumatologie, CHU Henri-Mondor, AP-HP, Université Paris Est Créteil, Créteil, France.
Study typeJournal article
Indexed viaPubMed
Source typeResearch paper
PublishedAug 5, 2026, 12:00 AM
Content availableJournal abstract

Conflict statement: Competing interests: A–AC: has received honoraria for lectures from UCB. BP, PLC, SF, AL and MD: no conflicts of interest to declare. PC: has received consulting fees from AbbVie, Amgen, Biogen, Celltrion, Galapagos, Janssen, Lilly, MSD, Novartis, Pfizer and UCB (<US$10 000 each) and has been an investigator for AbbVie, Janssen, Lilly, MSD, Novartis and Pfizer. LPV: has received consulting fees from Celltrion, AbbVie, UCB and Novartis, honoraria for lectures from UCB, Lilly, Novartis and Pfizer and financial support to attend meetings from Celltrion and UCB.

This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.

Related Reading

Browse latest news →